Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Myelodysplastic Syndromes (MDS)
Interventions: Azacitidine, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 13
States / cities: Tucson, Arizona • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 4
States / cities: San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more

Conditions: Mid Face Volume Deficit
Interventions: JUVÉDERM VOLUX XC, JUVÉDERM VOLUMA XC, JUVÉDERM VOLBELLA XC, JUVÉDERM VOLLURE XC, SKINVIVE by JUVÉDERM, JUVÉDERM ULTRA XC, JUVÉDERM ULTRA PLUS XC; Device
Lead sponsor: AbbVie; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Vista, California + 7 more

Conditions: Dry Eye Syndrome, Systemic Lupus Erythematosus
Interventions: ABBV-319; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Avon Park, Florida • Clearwater, Florida • Margate, Florida + 4 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Venetoclax; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 59 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity
Interventions: ABBV-295, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Breast Reconstruction
Interventions: ARTIA Reconstructive Tissue Matrix; Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 20 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Acalabrutinib, Venetoclax; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 4
States / cities: Boston, Massachusetts • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Hematologic Cancer
Interventions: ABBV-101, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 14
States / cities: Tucson, Arizona • Orange, California • Palo Alto, California + 11 more

Conditions: Diabetic Retinopathy, DR
Interventions: Standard of Care, Aflibercept; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 17 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: Standard of Care, Ranibizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 13 more

Conditions: Healthy Volunteer
Interventions: ABBV-722, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

About this AbbVie sponsor directory page